Effects of TAK-480, a novel tachykinin NK(2)-receptor antagonist, on visceral hypersensitivity in rabbits and ricinoleic acid-induced defecation in guinea pigs.
TAK-480, 4-(difluoromethoxy)-N-((1R,2S)-2-(((3aR,4R,9bR)-4-(methoxymethyl)-2, 3,3a,4,5,9b-hexahydro-1H-pyrrolo[3,2-c]quinolin-1-yl)carbonyl)cyclohexyl)benzamide, is a novel tachykinin NK(2)-receptor antagonist. In this study, we investigated its antagonistic activity and efficacy in animal models of visceral hypersensitivity and stimulated bowel function which have been implicated to underlie the symptoms in irritable bowel syndrome (IBS). TAK-480 showed potent binding affinity for human NK(2) receptors with a marked species difference and a 10,000-fold selectivity versus NK(1) and NK(3) receptors. TAK-480 dose-dependently antagonized colonic contractions induced by administration of the NK(2) receptor-selective agonist beta-Ala(8)-NKA(4-10) (βA-NKA) in anesthetized rabbits. In a rabbit model of intracolonic zymosan-induced visceral hypersensitivity, TAK-480 markedly inhibited the visceromotor response to colorectal distension, in contrast to the moderate inhibition by the serotonin 5-HT(3)-receptor antagonist alosetron. In addition, TAK-480 suppressed ricinoleic acid-induced defecation without affecting spontaneous defecation in guinea pigs, whereas alosetron suppressed both. Furthermore, TAK-480 inhibited smooth muscle contractions produced by natural tachykinins (substance P, neurokinin A, and neurokinin B) as well as βA-NKA in an isolated human colon. In conclusion, the novel NK(2)-receptor antagonist TAK-480 improved visceral hypersensitivity and accelerated defecation without causing constipation in experimental animals. Furthermore, the potent functional blockade of NK(2) receptors in human colon might suggest the potential effectiveness of TAK-480 in IBS patients.
Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa 251-8555, Japan.
Takahiro
T
Tanaka
Akiko
A
Tanaka
Akihiro
A
Nakamura
Kozo
K
Matsushita
Akio
A
Imanishi
Shiho
S
Matsumoto-Okano
Nobuhiro
N
Inatomi
Kasei
K
Miura
Masao
M
Toyoda
Gaku
G
Mizojiri
Yasuhiro
Y
Tsukimi
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D002460:Cell Line; D003106:Colon / Q000187:drug effects* / Q000502:physiology; D003672:Defecation / Q000187:drug effects*; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D006967:Hypersensitivity; D066298:In Vitro Techniques; D043183:Irritable Bowel Syndrome; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D011804:Quinolines / Q000494:pharmacology*; D011817:Rabbits; D018040:Receptors, Neurokinin-1 / Q000378:metabolism; D018041:Receptors, Neurokinin-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D018042:Receptors, Neurokinin-3 / Q000378:metabolism; D012277:Ricinoleic Acids
C577902:4-(difluoromethoxy)-N-(2-((4-(methoxymethyl)-2,3,3a,4,5,9b-hexahydro-1H-pyrrolo(3,2-c)quinolin-1-yl)carbonyl)cyclohexyl)benzamide; D001549:Benzamides; D011804:Quinolines; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D012277:Ricinoleic Acids; C030521:ricinoleic acid